CAR shares jump 28% in a month as pricing improves, fleet utilization hits a 15-year high and earnings are projected to surge in 2026.
Lyell Immunopharma (LYLE) offers asymmetric upside, with ronde-cel showing best-in-class durability and safety in relapsed/refractory LBCL. LYLE trades near cash value, with the market heavily discounting its pipeline despite advanced pivotal trials and strong early efficacy signals. Ronde-cel's dual CD19/CD20 targeting and CD62L+ enrichment underpin durable responses, low severe toxicity, and potential for outpatient administration.
Caribou Biosciences NASDAQ: CRBU Chief Executive Officer Rachel Haurwitz said the company is advancing two CRISPR-enabled, off-the-shelf CAR T cell therapy programs, with its lymphoma candidate vispa-cel now “pivotal-ready” and its multiple myeloma program CB-011 continuing in Phase 1 development.
| Transportation Infrastructure Industry | Industrials Sector | Brian J. Choi CEO | XETRA Exchange | US0537741052 ISIN |
| US Country | 17,000 Employees | 21 Dec 2023 Last Dividend | 5 Sep 2006 Last Split | 12 Jan 1990 IPO Date |
Avis Budget Group, Inc. operates as a comprehensive provider of mobility solutions, catering to both business and consumer needs across various geographical realms including the Americas, Europe, the Middle East and Africa, Asia, and Australasia. With its roots tracing back to 1946 and a rebranding from Cendant Corporation in September 2006, this entity has grown into a formidable platoon in the mobility services domain, headquartered in Parsippany, New Jersey. Through its diverse portfolio of brands — Avis, Budget, Zipcar, and several others — the company is strategically positioned across different market segments, from premium commercial and leisure travel to value-conscious consumer segments.
Avis Budget Group, Inc. boasts a wide range of mobility solutions and ancillary products and services, addressing the varied necessities of its clientele. Here's an overview of their primary offerings: